1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 05/24 11:00:00 am
746.8 DKK   -0.67%
03:46aNOVO NORDISK : Deutsche Bank remains its Buy rating
MD
05/23Novo Nordisk A/S – Share repurchase programme
GL
05/20European ADRs Move Sharply Higher in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Goldman Sachs remains its Buy rating

01/26/2022 | 02:47am EDT

Keyur Parekh from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price is set at 802 versus 822 DKK.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
03:46aNOVO NORDISK : Deutsche Bank remains its Buy rating
MD
05/23Novo Nordisk A/S – Share repurchase programme
GL
05/20European ADRs Move Sharply Higher in Friday Trading
MT
05/20NOVO NORDISK : Berenberg remains Neutral
MD
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 166 B 23 971 M 23 971 M
Net income 2022 52 875 M 7 627 M 7 627 M
Net cash 2022 4 087 M 589 M 589 M
P/E ratio 2022 32,0x
Yield 2022 1,53%
Capitalization 1 707 B 245 B 246 B
EV / Sales 2022 10,2x
EV / Sales 2023 9,04x
Nbr of Employees 49 295
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 751,80 DKK
Average target price 791,88 DKK
Spread / Average Target 5,33%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S2.29%245 087
JOHNSON & JOHNSON4.89%472 179
PFIZER, INC.-10.45%296 704
ROCHE HOLDING AG-14.40%273 052
ELI LILLY AND COMPANY9.55%272 388
ABBVIE INC.9.33%261 585